1 Organisation mondiale de la Santé. (2015). Critères de recevabilité médicale pour l’adoption et l’utilisation continue de méthodes contraceptives; 5
e édition.
https://www.who.int/reproductivehealth/publications/family_planning/MEC-5/fr/
2 Organisation mondiale de la Santé. (2016). Une sélection de recommandations pratiques relatives à l’utilisation de méthodes contraceptives; 3
e édition.
https://www.who.int/reproductivehealth/publications/family_planning/fr/
3 Davis SR, Bitzer J, Giraldi A, Palacios S, et al. Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in Women with oral contraceptive-associated sexual dysfunction. J Sex Med. 2013;10:3069–79.
4 Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study. Am J Obstet Gynecol. 2017;216(6):580.e1–580.e9.
5 Mørch LS, Skovlund CW, Hannaford PC, Iversen L, et al. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017;377:2228–39.
6 Merki-Feld GS, Bitzer J, Seydoux J, Birkhäuser M. SSGO Avis d’experts No. 35: Risque thromboembolique sous contraception hormonale; juin 2013.
7 Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Practice Committee of the American Society for Reproductive Medicine. Fertil Steril. 2017;107(1):43–51.
8 Wiebe E, Trussell J. Discontinuation rates and acceptability during 1 year of using the intrauterine ball (the SCu380A). Contraception. 2016;93(4):364–6.
9 O’Brien P, Marfleet CC. Frameless versus classical intrauterine device for contraception. Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD003282.
10 Stoegerer-Hecher E, Kirchengast S, Huber JC, Hartmann B. Amenorrhea and BMI as independent determinants of patient satisfaction in LNG-IUD users: cross-sectional study in a Central European district. Gynecol Endocrinol. 2012;28(2):119–24.
11 Mejia M, McNicholas C, Madden T, Peipert JF. Association of baseline bleeding pattern on amenorrhea with levonorgestrel intrauterine system use. Contraception. 2016;94(5):556–60.
12 Heinemann K, Reed S, Moehner S, et al. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices. Contraception. 2015;91:280–3.
14 Curtis KM, Ravi A, Gaffield ML. Progestogen-only contraceptive use in obese women. Contraception. 2009;80:346–54.
16 ESHRE Capri Workshop Group. Female contraception over 40. Hum Reprod Update. 2009;15(6):599–612.
17 Oppelt PG, Baier F, Fahlbusch C, Heusinger K, et al. What do patients want to know about contraception and which method would they prefer? Arch Gynecol Obstet. 2017;295(6):1483–91.